Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1Breast 1

Conditions

Multiple Myeloma 14Lymphoma, Non-Hodgkin 12Leukemia, Myeloid, Acute 12Leukemia 5Hodgkin Disease 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Chemotherapy-induced Neutropenia 3Breast Neoplasms 3Small Cell Lung Carcinoma 2Plasmacytoma 2Paraproteinemias 2Neutropenia 2Neoplasm Metastasis 2Leukemia, Plasma Cell 2Chemotherapy Induced Neutropenia 2Carcinoma, Non-Small-Cell Lung 2Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms by Histologic Type 1Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

pegfilgrastim 1MYL-1401H 1Long-Term Synaptic Depression 1Granulocyte Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Chemotherapy-Induced Febrile Neutropenia × Granulocyte Colony-Stimulating Factor × Clear all
NCT02467868 2022-02-14

Efficacy and Safety Study With MYL-1401H and Neulasta

Viatris Inc.

Phase 3 Completed
193 enrolled
BreastClassical hematology

Breast Neoplasms, Neutropenia, Chemotherapy-Induced Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡